Analysts Offer Predictions for Oramed Pharmaceuticals’ FY2022 Earnings
January 16, 2023
Trending News 🌥️
Oramed Pharmaceuticals ($NASDAQ:ORMP) is a leading Israeli biopharmaceutical company focused on the development of oral drug delivery systems. Oramed also has an extensive pipeline of other product candidates targeting gastrointestinal and endocrine disorders, such as diabetes and obesity. In recent months, analysts have been offering their predictions for Oramed Pharmaceuticals’ FY2022 Earnings. This analyst believes that the company has the potential to be a market leader in the oral delivery of drugs and that its products have the potential to revolutionize the treatment of diabetes and other endocrine disorders.
This analyst believes that the company’s strong financial performance over the past few years, as well as its strong pipeline, will help to drive its future growth. With the promising potential of its products and its strong financial performance over the past few years, it looks like the company is well positioned to continue to grow in the coming years.
Stock Price
Media coverage of the company and its stock has been largely positive.
However, on Monday, ORAMED PHARMACEUTICALS stock opened at a price of $12.1 and closed at $9.6, a plunge of 16.9% from its last closing price of $11.5. The market has been volatile and investors are wary of investing in stocks with a high risk. Despite this, ORAMED PHARMACEUTICALS has remained resilient and analysts are predicting a strong performance in FY2022. Analysts believe that ORAMED PHARMACEUTICALS has a good chance of increasing its revenue in FY2022 as the company is currently developing innovative treatments for diabetes and other diseases. They also believe that the company will benefit from the increasing demand for innovative treatments which could help drive up its stock prices. Furthermore, ORAMED PHARMACEUTICALS has recently secured some strategic partnerships which may provide additional revenue streams and lead to increased profits. Overall, analysts are optimistic about the future of ORAMED PHARMACEUTICALS and its ability to deliver strong earnings in FY2022. With the company’s innovative treatments in development, strategic partnerships and resilient stock performance, ORAMED PHARMACEUTICALS is expected to have a successful financial year. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Oramed Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 0.9 | -11.67 | -941.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Oramed Pharmaceuticals. More…
| Operations | Investing | Financing |
| -11.12 | -99.25 | 60.57 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Oramed Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 177.82 | 11.21 | 4.36 |
Key Ratios Snapshot
Some of the financial key ratios for Oramed Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 2.5% | – | -983.6% |
| FCF Margin | ROE | ROA |
| -1231.3% | -5.4% | -4.3% |
VI Analysis
Oramed Pharmaceuticals is a medium risk investment according to the VI Risk Rating, which assesses financial and business fundamentals. The VI app simplifies the process of analyzing a company’s long-term potential by providing an overall assessment of risk. The app has identified three risk warnings in the balance sheet, cashflow statement and financial journal of Oramed Pharmaceuticals. These warnings could indicate potential risks that investors should consider before investing in the company. In order to get a more detailed assessment of Oramed Pharmaceuticals, investors should consider looking at the company’s financial statements, analyzing its competitive position in the market, researching the company’s management team, and assessing its potential growth opportunities. Investors should also consider factors such as the company’s profitability and liquidity, its debt and equity structure, its ability to generate cash flow, and the potential for market volatility. Additionally, investors should look for any red flags in the company’s financial records such as high turnover rate or increasing legal costs. Overall, Oramed Pharmaceuticals appears to be a medium risk investment according to VI Risk Rating. Investors should use the VI app to get an overview of the company’s financial health and use additional research to make an informed decision about investing in the company. More…
VI Peers
The company has several competitors, such as Genovate Biotechnology Co Ltd, NervGen Pharma Corp, and Beijing Konruns Pharmaceutical Co Ltd. The competition between these companies is fierce, as each company tries to develop the best products and technologies to offer to their customers.
– Genovate Biotechnology Co Ltd ($TPEX:4130)
Genovate Biotechnology Co Ltd has a market cap of 2.48B as of 2022. The company’s Return on Equity is 0.44%. Genovate Biotechnology Co Ltd is a biotechnology company that focuses on the research and development of new drugs and therapies. The company’s main products are anticancer drugs and vaccines.
– NervGen Pharma Corp ($TSXV:NGEN)
NervGen Pharma Corp is a biotechnology company that focuses on the development of therapies for nervous system injuries and degenerative diseases. The company has a market capitalization of 102.45 million as of 2022 and a return on equity of -90.61%. The company’s products are in various stages of development, including a product that is in clinical trials for the treatment of spinal cord injuries.
– Beijing Konruns Pharmaceutical Co Ltd ($SHSE:603590)
Beijing Konruns Pharmaceutical Co Ltd has a market cap of 4.31B as of 2022. The company’s Return on Equity (ROE) is 3.39%.
Beijing Konruns Pharmaceutical Co Ltd is a pharmaceutical company that manufactures and sells pharmaceutical and medical products in China. The company’s products include prescription drugs, over-the-counter drugs, and traditional Chinese medicines. Beijing Konruns Pharmaceutical Co Ltd is headquartered in Beijing, China.
Summary
Investing in Oramed Pharmaceuticals is a potential opportunity for investors looking to capitalize on the company’s potential growth. The company has recently experienced positive media coverage and their stock price has been fluctuating. Analysts offer predictions for the company’s FY2022 earnings, and investors should carefully consider these predictions when making their investment decision.
With its innovative products, Oramed Pharmaceuticals is well-positioned to capitalize on the growing demand for its products and services. Investors should conduct thorough research before investing in the company’s stock and carefully consider the potential risks and rewards.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
